News | November 19, 2018

Urine Tests Can Show Patient Compliance With Blood Pressure Medication

Doctors from Leicester’s Hospitals and the University of Leicester show simple process may save NHS millions.

A urine test can show patient compliance with taking their hypertension, high blood pressure, medications.

November 16, 2018 — A research team led by scientists and doctors in Leicester and the Netherlands has shown that a urine test to measure whether patients are taking their medications will save the the U.K. National Health Service (NHS) money.

The research, published in the American Heart Association (AHA) journal Hypertension, was conducted in collaboration between the University of Leicester, Leicester’s Hospitals and University of Groningen, Netherlands.

Hypertension affects nearly one third of the population. Between 30 and 50 percent of patients with hypertension do not take all their medications as prescribed. It is estimated that this non-adherence costs the NHS millions of pounds in managing poor health outcomes and ordering costly tests to find out why patients’ blood pressure is not reduced.

The team led by Dr. Pankaj Gupta and Dr. Prashanth Patel, researchers based at the University of Leicester and Leicester’s Hospitals, has developed an innovative screening test which can detect non-adherence for 40 of the most commonly used blood pressure medications, all from a single urine sample. They have previously shown that using the test has positive results with blood pressure dropping by around 20 points (the equivalent of 2 new medications) once the results of the tests were discussed with non-adherent patients.
 
This study builds on from the previous research by modeling the health economics of using the test in patients with hypertension. The new study shows that performing the urine test would not only lead to improvements in the care of people with hypertension, but that it is also highly likely to be cost-effective. 

Using the best available data, the modelling predicts that in a cohort of 10,000, 65-year-old male hypertensive patients, using the urine test would save £495 per person screened, and prevent more than 500 heart attacks and 300 strokes. This is because non-adherence to prescribed hypertension drugs has been shown to correlate with a higher risk of cardiovascular events. The savings are thought to be even greater for younger hypertensive patients.

“Clinically we know that the urine test is very useful in patient care," said Gupta, the senior co-author of the paper from the University of Leicester’s Department of Cardiovascular Sciences and co-director of the National Centre for Drug Adherence Testing (NCAT) based at Leicester’s Hospitals. "The new 2018 European Society of Cardiology (ESC) and European Society of Hypertension (ESH) Guidelines have also recently supported the use of this novel test to assess non-adherence. We are very pleased to show that urine biochemical screening is extremely cost-effective and hence we can now recommend its wider adoption.” 

“Non-adherence to prescribed medications not only costs the NHS huge amounts of money, it also leads to adverse outcomes for patients. Our novel biochemical test is robust and simple to use in busy clinics," said Patel, co-author of the paper, Co-Director of NCAT and Honorary Senior Lecturer at the University of Leicester.

The urine test was established in 2011 and NCAT receives samples from around 33 NHS hospitals across the U.K. It is foreseen that with the new ESC-ESH guidelines and results of this study the use of this test will be adopted by more hospitals and GP practices in the U.K. and abroad.

“Non-adherence is a major problem globally in people with chronic conditions such as hypertension, diabetes and heart disease," said Kamlesh Khunti, professor of primary care diabetes and vascular medicine at University of Leicester, director of the National Institute for Health Research (NIHR) CLAHRC East Midlands and a study co-author. "The aging population means that greater numbers of people are living with more than one chronic condition, so taking more tablets, which is leading to poor adherence. This study for the first time shows that a targeted simple assessment of people who are likely to be non-adherent and then intervening would lead to improved outcomes that are cost-effective for the NHS.” 

The paper, “Cost-utility of an objective biochemical measure to improve adherence to antihypertensive treatment”, was published in Hypertension in October 2018.

 

Related Content

Plant-Based Diets Benefit Athletes' Heart Health, Endurance, Recovery
News | Cardiac Diagnostics | January 21, 2019
Meat-free athletes have already proven the performance-boosting power of a plant-based diet. Now, “Plant-Based Diets...
Sedentary Lifestyle Cancels Out Heart Benefits of Normal Weight
News | Cardiac Diagnostics | January 09, 2019
January 9, 2019 — Researchers at the University of Florida have found that low levels of physical activity can put he
Livongo Launches Applied Health Signals Product Category
News | Cardiac Diagnostics | November 30, 2018
Healthcare technology company Livongo recently announced the launch of its Applied Health Signals product category,...
HHS Releases Second Edition of Physical Activity Guidelines for Americans. #AHA2018 #AHA18
News | Cardiac Diagnostics | November 14, 2018
The U.S. Department of Health and Human Services (HHS) released the second edition of the Physical Activity Guidelines...
ACC and AHA Release Updated Cholesterol Guidelines for 2018. #AHA18 #AHA2018
Feature | Cardiac Diagnostics | November 13, 2018
November 13, 2018 — New cholesterol guidelines from the American Heart Association (AHA) and the American College of
AMI READMITS Score Predicts Heart Attack Patients at High Readmission Risk
News | Cardiac Diagnostics | October 09, 2018
Tracking just seven factors of heart attack patients when they are first admitted to the hospital can help flag those...
Siemens Healthineers Showcases New In Vivo and In Vitro Cardiovascular Solutions at TCT 2018
News | Cardiac Diagnostics | September 21, 2018
At the 2018 Transcatheter Cardiovascular Therapeutics (TCT) conference, Sept. 21-25 in San Diego, Siemens Healthineers...
Weight Loss Drug Does Not Increase Cardiovascular Events
News | Cardiac Diagnostics | August 31, 2018
A weight loss drug does not increase cardiovascular events, according to late breaking results from the CAMELLIA-TIMI...
Acarix Presents CADScor System at ESC 2018
News | Cardiac Diagnostics | August 27, 2018
Acarix AB’s ultra-sensitive acoustic CADScor System for coronary artery disease risk assessment will be on display at...
NIH Ending Funding for Moderate Alcohol and Cardiovascular Health Trial
News | Cardiac Diagnostics | August 24, 2018
The National Institutes of Health announced in June it plans to end funding to the Moderate Alcohol and Cardiovascular...
Overlay Init